Research digest.pdf – Remdesivir for the Treatment of Covid-19 u2014 Final Report J.H Beigel K.M Tomashek L.E Dodd A.K Mehta B.S Zingman A.C Kalil E

Remdesivir
for
the
Treatment
of
Covid-19
—
Final
Report
J.H. Beigel, K.M. Tomashek, L.E. Dodd, A.K. Mehta, B.S. Zingman, A.C. Kalil, E. Hohmann,
H.Y. Chu, A. Luetkemeyer, S. Kline, D. Lopez de Castilla, R.W. Finberg, K. Dierberg, V. Tapson,
L.
Hsieh, T.F. Patterson, R. Paredes, D.A. Sweeney, W.R. Short, G. Touloumi, D.C. Lye, N. Ohmagari,
M.
Oh, G.M. Ruiz-Palacios, T. Benfield, G. Fätkenheuer, M.G. Kortepeter, R.L. Atmar, C.B. Creech,
J. Lundgren, A.G. Babiker, S. Pett, J.D. Neaton, T.H. Burgess, T. Bonnett, M. Green, M. Makowski,
A. Osinusi, S. Nayak, and
H.C. Lane, for the ACTT-1 Study Group Members*
I.
INTRODUCTION
1. Given the topic, what area
is the “gap” or
least
explored?
Despite the availability of numerous
trials on therapeutically active substances
to
combat
the
effects
of
Covid-19
infections, there is still lack of evaluation of
medication that are capable of directly
targeting viruses and their capability to
reproduce.
SCORE
3 pts.
2.
What
is
the
study
investigating
(research
problem)?
The study evaluated the clinical
efficacy and safety of the antiviral drug
remdesivir
against
placebo
among
hospitalized
adults
with
laboratoryconfirmed CoVID-19.